Showing results (561-570 of 601) with videos related to

Sort By:
Pageof 61
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2018
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalban, Ralf Gold, Alan J Thompson, et al.
Plos One|November 3, 2016
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisDelphine Bachelet, Signe Hässler, Cyprien Mbogning, et al.
Plos One|February 8, 2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test resultsJenny Link, Ryan Ramanujam, Michael Auer, et al.
Annals of Neurology|December 30, 2021
Subcortical Volumes as Early Predictors of Fatigue in Multiple SclerosisVinzenz Fleischer, Dumitru Ciolac, Gabriel Gonzalez-Escamilla, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 26, 2021
CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune EncephalitisMarc Dürr, Gunnar Nissen, Kurt-Wolfram Sühs, et al.
Pain|March 21, 2020
Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort studyHenrik Heitmann, Bernhard Haller, Laura Tiemann, et al.
Ebiomedicine|May 28, 2020
Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort studyStefan Bittner, Falk Steffen, Timo Uphaus, et al.
Nature Communications|June 19, 2024
Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosisJulia Krämer, Carolin Balloff, Margit Weise, et al.
The Lancet. Neurology|July 23, 2011
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLudwig Kappos, David Bates, Gilles Edan, et al.
Pageof 61